BOSTON--(BUSINESS WIRE)--The Life Sciences Practice of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented its client, Boston Biomedical, Inc. (BBI), in the company’s definitive agreement to be acquired by Dainippon Sumitomo Pharma Co., Ltd. (DSP). Under the terms of the agreement, DSP will acquire BBI for up to $2.63 billion in total, which includes $200 million upfront, up to $540 million in development milestone payments, and up to $1.89 billion in sales milestone payments.
